Across TCGA pan-cancer cohorts, ST3GAL4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ST3GAL4 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ST3GAL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ST3GAL4 expression acts as an unfavorable survival marker.
UCEC are the cancer types where ST3GAL4 Mutation most reproducibly stratifies survival.